# Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy

> **NCT01718158** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 444 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **BIOLOGICAL:** Peginterferon Lambda-1a
- **BIOLOGICAL:** Peginterferon Alfa-2a
- **DRUG:** Ribavirin
- **DRUG:** Daclatasvir
- **DRUG:** Telaprevir

## Key facts

- **NCT ID:** NCT01718158
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 444 (ACTUAL)
- **Last updated:** 2015-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01718158

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01718158, "Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01718158. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*